Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food effect study of NTQ5082 in healthy subjects
NCT06558656Phase 1Not yet recruiting
- Sponsor
- Nanjing Chia-Tai Tianqing Pharmaceutical
- Start
- Aug 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of NTQ5082 in Complement-dependent hemolytic anemia (CDHA) (2 arms), sponsored by Nanjing Chia-Tai Tianqing Pharmaceutical. Primary endpoints: Area Under the Curve from time 0 to the last measurable concentration up to 15 days, Area Under the Curve from time 0 to infinity up to 15 days and 5 more. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
NTQ5082
03
Conditions
Complement-dependent hemolytic anemia (CDHA)
Beyond the preview
Go deeper on NCT06558656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06558656.